Skip to content

Mission

We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.

Latest Portfolio Company News

Latest Press Releases

Interim report Q3 2024

The interim report for the third quarter 2024 will be published on Wednesday October 16 at 08:00 CEST.

Presentation: the same day at 11:00 CEST.